http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101147409-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-108 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8778 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate | 2010-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101147409-B1 |
| titleOfInvention | Transgenic porcine clone somatic cell line expressing human FSL protein for cellular immune suppression and transgenic cloned pig using the same |
| abstract | The present invention relates to a transgenic cloned pig clone somatic cell line expressing human FasL (hFasL) gene, which is a human immunogene, in tissues and cells, and more particularly, to 1) somatic cells from a pig embryo. Separating; 2) preparing an expression vector comprising the hFasL gene and introducing the isolated somatic cell; And 3) relates to a method for producing a transgenic pig clone somatic cell line expressing a human FasL protein comprising the step of selecting and culturing the somatic cells introduced with the expression vector and a pig clone somatic cell line produced by the method. Porcine clone somatic cell lines of the present invention express the membrane-bound form of hFasL to reduce cytotoxicity by CTL and natural killer cells, thereby minimizing immune rejection by CTL and natural killer cells, It can be usefully used for transplant research and its industrial use. |
| priorityDate | 2010-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 148.